NasdaqGS - Delayed Quote USD

Puma Biotechnology, Inc. (PBYI)

2.9100
-0.1600
(-5.21%)
At close: May 9 at 4:00:00 PM EDT
2.9001
-0.01
(-0.34%)
After hours: May 9 at 6:29:09 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
230,468
230,468
235,637
228,031
253,155
Cost of Revenue
64,404
64,404
62,682
55,093
63,701
Gross Profit
166,064
166,064
172,955
172,938
189,454
Operating Expense
135,098
135,098
139,690
142,218
188,164
Operating Income
30,966
30,966
33,265
30,720
1,290
Net Non Operating Interest Income Expense
-7,728
-7,728
-10,725
-10,779
-12,647
Other Income Expense
862
862
134
-19,484
-17,445
Pretax Income
24,100
24,100
22,674
457
-28,802
Tax Provision
-6,178
-6,178
1,083
455
324
Net Income Common Stockholders
30,278
30,278
21,591
2
-29,126
Diluted NI Available to Com Stockholders
30,278
30,278
21,591
2
-29,126
Basic EPS
0.62
--
0.46
0.00
-0.72
Diluted EPS
0.62
--
0.45
0.00
-0.72
Basic Average Shares
48,648.7010
--
47,134.3310
44,674.5010
40,638.8520
Diluted Average Shares
49,100.4330
--
47,550.8520
44,929.9980
40,638.8520
Total Operating Income as Reported
30,966
30,966
32,640
23,720
1,290
Total Expenses
199,502
199,502
202,372
197,311
251,865
Net Income from Continuing & Discontinued Operation
30,278
30,278
21,591
2
-29,126
Normalized Income
30,278
30,278
22,186.1475
15,372.2400
-16,177.9900
Interest Income
4,724
4,724
2,605
813
160
Interest Expense
12,452
12,452
13,330
11,592
12,807
Net Interest Income
-7,728
-7,728
-10,725
-10,779
-12,647
EBIT
36,552
36,552
36,004
12,049
-15,995
EBITDA
48,076
48,076
47,523
21,889
-4,690
Reconciled Cost of Revenue
64,404
64,404
62,682
55,093
63,701
Reconciled Depreciation
11,524
11,524
11,519
9,840
11,305
Net Income from Continuing Operation Net Minority Interest
30,278
30,278
21,591
2
-29,126
Total Unusual Items Excluding Goodwill
0
0
-625
-19,456
-17,737
Total Unusual Items
0
0
-625
-19,456
-17,737
Normalized EBITDA
48,076
48,076
48,148
41,345
13,047
Tax Rate for Calcs
0.0002
0.0002
0
0.0002
0.0003
Tax Effect of Unusual Items
0
0
-29.8525
-4,085.7600
-4,788.9900
12/31/2021 - 4/24/2012

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

VIR Vir Biotechnology, Inc.
5.09
-6.01%
 
INVA Innoviva, Inc.
18.56
-0.11%
 
BLUE bluebird bio, Inc.
3.5000
-5.66%
 
ACAD ACADIA Pharmaceuticals Inc.
17.44
+3.01%
 
VNDA Vanda Pharmaceuticals Inc.
3.9500
-6.40%
 
NKTR Nektar Therapeutics
0.5887
-4.88%
 
ALXO ALX Oncology Holdings Inc.
0.4223
-8.24%
 
CTMX CytomX Therapeutics, Inc.
0.9284
-14.83%
 
KPTI Karyopharm Therapeutics Inc.
6.01
-2.28%
 
CHRS Coherus BioSciences, Inc.
0.9687
-2.38%